RUSNANO Invests in Selecta Biosciences and BIND Biosciences to Develop and Commercialize Vaccines and Cancer Drugs in Russia

BIND Biosciences and Selecta Biosciences, two leading nanomedicine companies, announced today that they have entered into investment agreements with RUSNANO, a $10-billion Russian Federation fund that supports high-tech and nanotechnology advances.

Related Posts

Comments are closed.